2658 related articles for article (PubMed ID: 7711115)
21. Structure and expression of the chicken epidermal growth factor receptor gene locus.
Olofsson B; Pizon V; Zahraoui A; Tavitian A; Therwath A
Eur J Biochem; 1986 Oct; 160(2):261-6. PubMed ID: 3769926
[TBL] [Abstract][Full Text] [Related]
22. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
Boerner JL; Danielsen AJ; Lovejoy CA; Wang Z; Juneja SC; Faupel-Badger JM; Darce JR; Maihle NJ
Oncogene; 2003 Oct; 22(43):6679-89. PubMed ID: 14555981
[TBL] [Abstract][Full Text] [Related]
23. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors.
Yamazaki H; Ohba Y; Tamaoki N; Shibuya M
Jpn J Cancer Res; 1990 Aug; 81(8):773-9. PubMed ID: 2168866
[TBL] [Abstract][Full Text] [Related]
24. Differences in sequences encoding the carboxyl-terminal domain of the epidermal growth factor receptor correlate with differences in the disease potential of viral erbB genes.
Gamett DC; Tracy SE; Robinson HL
Proc Natl Acad Sci U S A; 1986 Aug; 83(16):6053-7. PubMed ID: 3016739
[TBL] [Abstract][Full Text] [Related]
25. The erbB gene and the EGF receptor.
Martin GS
Cancer Surv; 1986; 5(2):199-219. PubMed ID: 2877733
[TBL] [Abstract][Full Text] [Related]
26. A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein.
Lehtola L; Lehväslaiho H; Koskinen P; Alitalo K
Acta Oncol; 1992; 31(2):147-50. PubMed ID: 1352454
[TBL] [Abstract][Full Text] [Related]
27. A chimeric EGFR/neu receptor in studies of neu function.
Lehtola L; Lehväslaiho H; Koskinen P; Alitalo K
Cancer Treat Res; 1992; 61():213-28. PubMed ID: 1360234
[No Abstract] [Full Text] [Related]
28. High-affinity interleukin 2 binding by an oncogenic hybrid interleukin 2-epidermal growth factor receptor molecule.
Bernard O; Fazekas de St Groth B; Ullrich A; Green W; Schlessinger J
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2125-9. PubMed ID: 3104909
[TBL] [Abstract][Full Text] [Related]
29. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant.
Messerle K; Schlegel J; Hynes NE; Groner B
Mol Cell Endocrinol; 1994 Oct; 105(1):1-10. PubMed ID: 7821711
[TBL] [Abstract][Full Text] [Related]
30. Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis.
von Lindern M; Deiner EM; Dolznig H; Parren-Van Amelsvoort M; Hayman MJ; Mullner EW; Beug H
Oncogene; 2001 Jun; 20(28):3651-64. PubMed ID: 11439328
[TBL] [Abstract][Full Text] [Related]
31. Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors.
Haley JD; Hsuan JJ; Waterfield MD
Oncogene; 1989 Mar; 4(3):273-83. PubMed ID: 2784850
[TBL] [Abstract][Full Text] [Related]
32. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research.
Earp HS; Dawson TL; Li X; Yu H
Breast Cancer Res Treat; 1995 Jul; 35(1):115-32. PubMed ID: 7612898
[TBL] [Abstract][Full Text] [Related]
33. Allosteric regulation of the epidermal growth factor receptor kinase.
Schlessinger J
J Cell Biol; 1986 Dec; 103(6 Pt 1):2067-72. PubMed ID: 3023396
[No Abstract] [Full Text] [Related]
34. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
Connelly PA; Stern DF
Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718
[TBL] [Abstract][Full Text] [Related]
35. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells.
Ewald JA; Wilkinson JC; Guyer CA; Staros JV
Exp Cell Res; 2003 Jan; 282(2):121-31. PubMed ID: 12531698
[TBL] [Abstract][Full Text] [Related]
36. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa R; Ji XD; Harmon RC; Lazar CS; Gill GN; Cavenee WK; Huang HJ
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7727-31. PubMed ID: 8052651
[TBL] [Abstract][Full Text] [Related]
37. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
[TBL] [Abstract][Full Text] [Related]
38. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
39. The colony-stimulating factor 1 (CSF-1) receptor (c-fms proto-oncogene product) and its ligand.
Rettenmier CW; Roussel MF; Sherr CJ
J Cell Sci Suppl; 1988; 9():27-44. PubMed ID: 2978516
[TBL] [Abstract][Full Text] [Related]
40. A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides.
van der Geer P; Wiley S; Lai VK; Olivier JP; Gish GD; Stephens R; Kaplan D; Shoelson S; Pawson T
Curr Biol; 1995 Apr; 5(4):404-12. PubMed ID: 7542991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
